Office-use compounding in Virginia

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

Four elements, each load-bearingHigh confidence

A closed list of practitioner types — medicine, osteopathy, podiatry, dentistry, and no others are named; administration only; personally or under direct and immediate supervision; and the gate. The second limb of the gate is effectively empty for routine human office stock, because the federal statute it points to conditions its exemptions on an identified individual patient.Nurse practitioners, physician assistants and optometrists are not on the statutory list. That is the text; no authority extending it was found.

The veterinary limbs are gated differently from each otherHigh confidence

Office-based administration to the veterinarian’s own patients is unconditional. But compounded products for companion animals distributed by a pharmacy to a veterinarian for further distribution or sale to his own patients are limited to drugs necessary to treat an emergent condition when timely access to a compounding pharmacy is not available, as determined by the prescribing veterinarian.State both limbs in the same breath or neither. Describing the veterinary channel as unconditional is half right, and the half that is wrong is the half a reader would act on.

The label legend, which must be quoted exactlyHigh confidence

The legend is "For Administering in Prescriber Practice Location Only" — six words, capitalised as shown. It is the only office-use label legend among the states added in this batch, and any paraphrase of it is a compliance error a reader could act on.The labelling duty is tied to the same two gates as the permission itself. There is no label formula for a non-emergency, non-federally-allowed office shipment, because Virginia creates no such category.

Quantity — a standard, not a numberHigh confidence

"A reasonable amount", bounded in practice by the beyond-use date the label requires. There is no numeric cap. Separately, § 54.1-3410.2(H)(3) provides that compounding inordinate amounts with no observed historical prescribing pattern shall constitute manufacturing of drugs.

The 5% provision is a licensure exemptionHigh confidence

Section 54.1-3435.02(A) lets a permitted pharmacy engage in wholesale distributions of small quantities of prescription drugs without being licensed as a wholesale distributor, so long as those distributions stay within five per cent of its gross annual prescription drug sales. It exempts a pharmacy from a licence. It authorises no compounding, and it is not an office-use allowance.

Administer and dispense are drawn cleanly, and unusuallyHigh confidence

For practitioners of medicine or osteopathy, "dispense" includes only the provision of drugs by a practitioner to patients to take with them away from the practitioner’s place of practice. Everything given in the office is administration. The definition also excludes the transportation of drugs mixed, diluted or reconstituted in accordance with the chapter to other sites operated by that practitioner or that practitioner’s medical practice for the purpose of administration — a genuinely useful fact for a multi-site clinic.

A sterile-compounding notification that reaches out-of-state pharmaciesHigh confidence

Section 54.1-3410.2(K) requires the pharmacist-in-charge or owner of a permitted pharmacy, or of a registered nonresident pharmacy, engaging in sterile compounding to notify the Board of its intention to dispense or deliver a sterile compounded product into the Commonwealth, and to notify again at each renewal. Failure to do so is a violation.

Last change, and what is pendingHigh confidence

Section 54.1-3410.2 was amended in 2025 to add a health-system internal-distribution exception, effective 1 July 2025; the office-use paragraph itself was not changed. There has been no Board rulemaking on compounding, sterile compounding, the USP chapters or outsourcing facilities in 2025 or 2026 — the last action on outsourcing facilities became effective in 2017.A 2026 bill that would have amended this section was continued to 2027 and is not law; it would have restricted rather than expanded, adding certificate-of-analysis and FDA-inspection requirements for bulk substances. A Board fee increase takes effect 23 September 2026, so any fee figure on this page needs re-checking on that date.

Virginia at a glance

Receiving 503B office stock in Virginia

Virginia registers outsourcing facilities through its Board of Pharmacy, and the trigger carries no prescription qualifier — the first shipment attaches it. The thing that reframes everything else on the receiving side is definitional: in Virginia a "controlled substance" means Schedules I through VI, and Schedule VI captures every drug that must bear "Rx only".

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Virginia asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

A nonresident outsourcing facility registration with the Board of Pharmacy. Section 54.1-3434.5(A): "Any outsourcing facility located outside the Commonwealth that ships, mails, or delivers in any manner Schedule II through VI drugs or devices into the Commonwealth shall be considered a nonresident outsourcing facility and shall be registered with the Board." Note what is absent — there is no "pursuant to a prescription" qualifier, unlike the adjacent nonresident pharmacy provision, so the duty attaches to the first shipment. The application must be signed by a pharmacist licensed in Virginia who is in full and actual charge of the facility, and FDA registration plus a current FDA inspection report is required. The fee was $350 initial and $350 renewal.The Virginia-licensed pharmacist signature is a real operational barrier that catches facilities by surprise. The Board frames this as something a PRESCRIBER can get wrong too: its own guidance says a pharmacy or prescriber may not obtain a compounded sterile product from an out-of-state outsourcing facility that the Board has not registered. Structurally, the office-use gate does not bind an outsourcing facility at all — § 54.1-3434.5(D) exempts the paired registration from that section — which is the legal reason Virginia office stock is an outsourcing-facility channel rather than a pharmacy one.

Does your practice need a permit?Medium confidence

Not automatically, and both absolutes are wrong. A solo physician buying and administering to their own patients needs no controlled substances registration — § 54.1-3301(6) protects a practitioner purchasing, possessing or administering to their own patients, and the registration section expressly excepts licensed physicians. Several physicians each buying under their own licence with stock kept separate are outside it too on the plain text. Where a group practice shares COMMON stock, the Board may compel a registration, but only on a specific trigger: a large-purchase report, a diversion, theft or unusual loss, a recordkeeping failure, or a controlled-substance violation.The likeliest real-world path in is a theft report, which converts a voluntary registration into a mandatory one. Holding one is not free: it limits the entity to an approved drug list, and a change of responsible party, supervisor, ownership or storage location requires immediate surrender and a fresh application within 14 days. Its per-location character is inferred from the mechanics rather than stated.

Administer vs dispenseHigh confidence

Administering office stock is the clean case and adds no credential. Dispensing is three credentials, not one: the practitioner needs a Board licence to dispense, the facility needs a permit, and each dispensing physician in a practice needs their own licence — solo dispensers are exempt from the fee, not from the permit. "Free" is no defence, because "sale" is defined to include barter, exchange or gift, and the Board has said a charge is not required for dispensing to become a sale. A dispensing practice also faces physical requirements: stock maintained for ultimate sale kept separate from stock held for administration or samples, a dedicated enclosed area of not less than 40 square feet, a sink with hot and cold running water within 20 feet and not in an exam room or restroom, a break-in alarm, and patient-choice signage in the public area and every exam room.

Scheduled (controlled) stockHigh confidence

This is where Virginia inverts the usual analysis. "Controlled substance" means a drug in Schedules I through VI, and Schedule VI captures any drug required to bear "Rx only" — so compounded peptide or hormone stock with no DEA schedule at all is a controlled substance in Virginia, and the rules written about "Schedules II through VI" reach it. That includes the outsourcing-facility registration trigger, storage, security, recordkeeping and the alarm requirement. A reader who assumes those rules are irrelevant because the drug carries no DEA schedule has the analysis backwards here.The alarm rule bites because of that inversion: a facility not staffed 24 hours a day needs a break-in detection device with auxiliary power and outside monitoring, and the exemption list does not include ordinary medical practices or outpatient clinics. Theft or loss runs on two clocks — report immediately, then furnish the kind, quantity and strength within 30 days. Records run two years for a practice and five for an outsourcing facility.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• Whether an outsourcing facility also needs a Virginia wholesale distributor licence is unresolved, and the plain text leans toward yes: the wholesale exemption covers only permitted pharmacies and medical equipment suppliers, manufacturers get an express carve-out, and the outsourcing-facility permit section contains no equivalent sentence. The counter-evidence is regulatory silence. Neither answer should be published as settled.
• Whether a dispensing-licensed physician may lawfully purchase compounded stock outside an emergency is unresolved. The rule limits such a licensee to purchasing Schedule II through VI drugs from a wholesale distributor licensed or registered by the Board, and a compounding pharmacy operating under the 5% exemption is not one. Do not assert either way.
• The per-location character of a controlled substances registration is inferred from inspection and approval mechanics rather than stated in the text.
• Board guidance documents quoted on this page come from the source research and we did not re-verify them here, though we re-read every statute and administrative-code quotation directly. One guidance document is known to be stale — it still quotes the pre-2025 version of the subsection, without the health-system exception. Virginia’s regulatory town hall index is systematically stale on guidance titles and dates; the department’s own index is the current one.
• Our 2026 legislative scan covered bill titles, descriptions and summaries only, because the legislature’s interface returned empty full-text fields for every record. A bill that touches this subject without saying so in its summary would have been missed.